AboutPricingLoginBook a demo
AboutPricingLoginBook a demo

Transcenta

Ownership
Public
Employees
~88
Therapeutic Areas
OncologyNephrologyRheumatology
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Monoclonal antibodies (mAbs)Antibody-based biotherapeutics[1][2][3][5][6]

Transcenta General Information

Transcenta has a broad pipeline of over ten biologic programs focused on oncology and selected non-oncology indications such as bone and kidney diseases. Its lead program Osemitamab (TST001), targeting CLDN18.2 for gastric/gastroesophageal cancer, has reached global Phase III pivotal trials in combination with Nivolumab and chemotherapy. The company collaborates with Agilent Technologies for companion diagnostics development.[3][7] Other programs are at various clinical stages.

Contact Information

Website
https://www.transcenta.com/
Primary Industry
Biotech
Corporate Office
Hangzhou,
China

Drug Pipeline

osemitamab
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Transcenta's pipeline data

Book a demo

Key Partnerships

Agilent Technologies (companion diagnostic collaboration for CLDN18.2/Osemitamab)[7]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Transcenta Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Transcenta's complete valuation and funding history, request access »

Transcenta Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals